Abstract 12706: Carotid Plaque Lipid Content is Reduced After 6 Months of Proprotein Convertase Subtilisin Kexin Type 9 Inhibition With Alirocumab: an Interim Analysis of a Serial Magnetic Resonance Imaging Study

Jie Sun,Norman E. Lepor,Gador Canton,Laurn Contreras,Daniel S. Hippe,Daniel Isquith,Niranjan Balu,Ilan Kedan,Americo Simonini,Chun Yuan,Xue Qiao Zhao,Thomas S. Hatsukami

Abstract 12706: Carotid Plaque Lipid Content is Reduced After 6 Months of Proprotein Convertase Subtilisin Kexin Type 9 Inhibition With Alirocumab: an Interim Analysis of a Serial Magnetic Resonance Imaging Study

2019

Jie Sun
Norman E. Lepor
Gador Canton
Laurn Contreras
Daniel S. Hippe
Daniel Isquith
Niranjan Balu
Ilan Kedan
Americo Simonini
Chun Yuan
Xue Qiao Zhao
Thomas S. Hatsukami

Introduction: In the ODYSSEY OUTCOMES trial, proprotein convertase subtilisin kexin type 9 inhibition (PCSK9i) with alirocumab reduced recurrent major cardiovascular events by 15%, including 27% in...

Keywords:

Proprotein convertase
Kexin
Subtilisin
lipid content
Internal medicine
PCSK9
Alirocumab
Pharmacology
Medicine
Cardiology
Diabetes mellitus
Interim analysis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations